Newsletter

Supply Issues Persist for Sitagliptin (Januvia) as Generic Release Approaches

Supply Issues for Diabetes Medication ‘Sitagliptin’ Raises Concerns for Pharmaceutical Companies Several pharmaceutical companies are facing challenges in meeting the demand for generic DPP-4 inhibitors used in the treatment of diabetes, specifically ‘Sitagliptin’ (brand name: Januvia). One of the main obstacles lies in the limited production capacity of the contracted consignment companies, making it difficult […]